Blue Water Vaccines, a preclinical biotech developing vaccines for the flu and other infectious diseases, filed on Friday with the SEC to raise up to $24 million in an initial public offering.
Blue Water is focused on the research and development of transformational vaccines to prevent infectious diseases worldwide using its versatile vaccine platform, which can be utilized to develop singular or multi-targeted vaccines. Its pipeline includes novel vaccine candidates exclusively licensed from research institutions. The company's lead program, BWV-101, is licensed from the University of Oxford and is being developed as a transformational novel universal influenza vaccine.
The Cincinnati, OH-based company was founded in 2018 and plans to list on the Nasdaq under the symbol BWV. Blue Water Vaccines filed confidentially on August 23, 2021. Maxim Group LLC is the sole bookrunner on the deal. No pricing terms were disclosed.
